Hims & Hers stock soars in pre-market; Pfizer and Agilent Technologies decline

Investing.com - U.S. stock index futures fell sharply on Monday, as escalating Middle East conflicts pushed energy prices higher, sparking concerns about future economic growth.

Stay closely updated on U.S. stocks with InvestingPro

Here are the major pre-market movers today:

• Hims & Hers Health stock surged 43% after Bloomberg reported that Novo Nordisk (up 1.1%) plans to sell its weight-loss drugs through the telemedicine platform, marking an unexpected settlement between the two companies following recent legal disputes.

• WisdomTree stock declined 1.3% as the tech company prepares to release its Q1 earnings, with revenue expected to grow approximately 19-20% year-over-year to about $9.3 billion, mainly driven by demand for AI infrastructure.

• Pfizer stock dropped 1.6% after the pharmaceutical giant announced mid-stage clinical trial results for its experimental antibody therapy for atopic dermatitis.

• Agilent Technologies stock fell 1.4% after the life sciences company announced it will acquire private clinical pathology firm Biocare Medical in a $950 million all-cash deal.

• Aureus Greenway stock soared 47% following a Wall Street Journal report that the holding company will merge with Powerus, a drone manufacturer supported by President Trump’s son.

• Relmada Therapeutics stock jumped 32% after the biotech announced mid-term data from its Phase 2 trial evaluating treatments for high-risk non-muscle invasive bladder cancer patients over 12 months.

• ExxonMobil and Chevron both rose about 1%, benefiting from a sharp increase in crude oil prices as Middle East conflicts pushed Brent crude above $110 per barrel.

This article was translated with the assistance of AI. For more information, please see our Terms of Use.